🇺🇸 GSK plcGLAXF

Company Update Form 6-K 18-11-2026 07:06:13 EST

Subject: 6-K — Foreign issuer report

Overview: The FDA granted accelerated approval to Nelkarmi (neladalkib) for adults with previously-treated advanced ALK-positive non-small cell lung cancer.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest